Late effects from hadron therapy.
Successful cancer patient survival and local tumor control from hadron radiotherapy warrant a discussion of potential secondary late effects from the radiation. The study of late-appearing clinical effects from particle beams of protons, carbon, or heavier ions is a relatively new field with few data. However, new clinical information is available from pioneer hadron radiotherapy programs in the USA, Japan, Germany and Switzerland. This paper will review available data on late tissue effects from particle radiation exposures, and discuss its importance to the future of hadron therapy. Potential late radiation effects are associated with irradiated normal tissue volumes at risk that in many cases can be reduced with hadron therapy. However, normal tissues present within hadron treatment volumes can demonstrate enhanced responses compared to conventional modes of therapy. Late endpoints of concern include induction of secondary cancers, cataract, fibrosis, neurodegeneration, vascular damage, and immunological, endocrine and hereditary effects. Low-dose tissue effects at tumor margins need further study, and there is need for more acute molecular studies underlying late effects of hadron therapy.
Blakely
Eleanor A
EA
Life Science Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94620, USA. EABlakely@lbl.gov
Chang
Polly Y
PY
D002244:Carbon; D020450:Heavy Ions / Q000009:adverse effects*; D006371:Helium; D006801:Humans; D018499:Linear Energy Transfer; D009369:Neoplasms / Q000532:radiotherapy*; D011522:Protons / Q000009:adverse effects*; D011836:Radiation Tolerance; D012062:Relative Biological Effectiveness
D011522:Protons; D006371:Helium; D002244:Carbon